Literature DB >> 31954532

Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.

Dan Wang1, Shan Zhu1, Congwei Jia2, Dongyan Cao1, Ming Wu1, Keng Shen1, Jiaxin Yang1, Lingya Pan1, Ninghai Cheng1, Yang Xiang3.   

Abstract

OBJECTIVES: To evaluate the diagnostic, surgical, and oncological outcomes of patients with growing teratoma syndrome (GTS).
METHODS: Patients diagnosed with ovarian immature teratoma (IMT) between 1980 and 2018 at Peking Union Medical College Hospital (PUMCH) were evaluated for the development of GTS. Their clinical characteristics, surgical and pathological data, and oncological outcomes were collected.
RESULTS: Between 1980 and 2018, 175 cases of IMT were referred to PUMCH. Thirty-five patients subsequently developed GTS with a crude rate of approximately 20%. The median interval between the initial diagnosis of IMT and the first occurrence of GTS was 18.5 months (range, 6-78 months). Residual disease (P < 0.001) and gliomatosis peritonei (GP) at initial surgery (P = 0.023) were independent risk factors for GTS development. Fertility-sparing surgery for GTS was performed in 27 patients and four patients achieved five singleton pregnancies. The median follow-up time was 73 months (range, 11-401 months). Eleven patients developed at least one recurrence. Residual disease after GTS surgery was associated with GTS recurrence (P = 0.001). By the end of follow-up, 27 patients were alive without disease and the other eight patients were alive with disease.
CONCLUSION: The presence of residual disease and GP at initial surgery are risk factors for GTS. Complete surgical resection is the cornerstone for treatment of GTS. The presence of residual disease after surgery for GTS is a risk factor for GTS recurrence. Fertility-sparing surgery should be performed because spontaneous pregnancy is possible. The overall prognosis of GTS is excellent.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Adjuvant chemotherapy; Growing teratoma syndrome; Immature teratoma

Year:  2020        PMID: 31954532     DOI: 10.1016/j.ygyno.2019.12.042

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Oncological and Reproductive Outcomes in Patients With Advanced-Stage Ovarian Immature Teratoma: Experience From a Tertiary Center.

Authors:  Dan Wang; Wei Cang; Shan Zhu; Congwei Jia; Dongyan Cao; Jiaxin Yang; Yang Xiang
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

2.  Ovarian growing teratoma syndrome with multiple metastases in the abdominal cavity and liver: A case report.

Authors:  Xu Hu; Zhong Jia; Li-Xin Zhou; Nisile Kakongoma
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

Review 3.  Growing Teratoma Syndrome in the Setting of Sarcoidosis: A Case Report and Literature Review.

Authors:  Adel Shahnam; Robyn Sayer; Unine Herbst; Raghwa Sharma; Won-Hee Yoon; Tim Dinihan; Bo Gao
Journal:  Curr Oncol       Date:  2022-06-07       Impact factor: 3.109

4.  Pelvic masses after surgery for immature ovarian teratoma: A 10-year experience of Western China.

Authors:  Sixia Xie; Xibiao Jia; Tingting Li; Yuanyuan Xu; Weiwei Wu; Yichao Qiu; Shuang Yuan; Xue Peng; Hongjing Wang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

Review 5.  Growing Teratoma Syndrome with Synchronous Gliomatosis Peritonei during Chemotherapy in Ovarian Immature Teratoma: A Case Report and Literature Review.

Authors:  Sijian Li; Na Su; Congwei Jia; Xinyue Zhang; Min Yin; Jiaxin Yang
Journal:  Curr Oncol       Date:  2022-09-04       Impact factor: 3.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.